BHC
Next earnings: Jul 29, 2026 · After close
Signal
Leaning Bearish1
Price
1
Move-0.55%Quiet session
Volume
1
Volume0.5× avgNormal activity
Technical
1
RSIRSI 32Momentum negative
PRICE
Prev Close
5.45
Open
5.44
Day Range5.30 – 5.49
5.30
5.49
52W Range4.41 – 8.69
4.41
8.69
24% of range
VOLUME & SIZE
Avg Volume
1.9M
FUNDAMENTALS
P/E Ratio
-1.7x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.33
Market-like
Performance
1D
-0.55%
5D
-4.91%
1M
-5.57%
3M
-9.52%
6M
-13.69%
YTD
-22.01%
1Y
+17.83%
Best: 1Y (+17.83%)Worst: YTD (-22.01%)
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +9% YoY · 62% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 1.3 · FCF $2.65/sh
Bullish
Key MetricsTTM
Market Cap$2.02B
Revenue TTM$10.55B
Net Income TTM-$1.19B
Free Cash Flow$989.53M
Gross Margin61.7%
Net Margin-11.3%
Operating Margin22.9%
Return on Equity120.7%
Return on Assets-4.9%
Debt / Equity-10.10
Current Ratio1.32
EPS TTM$-3.19

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong2 watch2 concern
52/100
Liquidity
1.32Watch
Leverage
-10.10Strong
Coverage
1.4xConcern
ROE
120.7%Strong
ROIC
11.6%Watch
Cash
$1.3BConcern
ANALYST COVERAGE36 analysts
HOLD
+47.6%upside to target
Buy
1953%
Hold
1336%
Sell
411%
19 Buy (53%)13 Hold (36%)4 Sell (11%)
Full report →
Stock Health
Composite Score
0 of 5 signals bullish
3/10
Technicals
RSI RangeRSI 32 — Bearish momentum
Volume
Volume FlowNeutral
~
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 1.32
~
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentSep 18, 2026
In 125 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendGolden Cross · 50D leads 200D by 4.9%

-14.4% vs SMA 50 · -10.2% vs SMA 200

Momentum

RSI31.9
Momentum fading
MACD-0.24
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$8.69+60.3%
EMA 50
$6.04+11.5%
EMA 200
$6.03+11.3%
Current
$5.42
52W Low
$4.41-18.6%
52-Week RangeNear 52-week low
$4.4124th %ile$8.69
Squeeze SetupVolume-based
No Clear Setup

Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.

20-Day Money Flow
Acc days:3
Dist days:4
Edge:+1 dist
Volume Context
Avg Vol (50D)1.6M
Recent Vol (5D)
1.5M-7%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 5 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$10.3B
$10.2B$10.3B
$3.87
±2%
Moderate4
FY2026(current)
$10.7B
$10.6B$10.7B
+3.9%$4.30+10.9%
±3%
Moderate4
FY2027
$10.6B
$10.6B$10.7B
-0.0%$4.14-3.7%
±10%
High5
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryBHC
Last 8Q
-7.8%avg beat
Beat 3 of 8 quartersMissed 5 Estimates falling
+1%
Q3'24
+9%
Q4'24
-30%
Q1'25
-29%
Q2'25
-7%
Q3'25
+8%
Q4'25
-11%
Q1'26
-4%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →
No recent activity
Piper SandlerNeutral → Underweight
Aug 1
DOWNGRADE
Insider Activity
SEC Filings →
1 Buy/5 SellsNet Selling
Carson SeanaEVP, General C…
$40K
Mar 2
SELL
Carson SeanaEVP, General C…
$26K
Mar 3
SELL
Carson SeanaEVP, General C…
$50K
Feb 27
SELL
Paulson & Co. Inc.10 Percent Own…
$15.6M
Nov 25
BUY
Carson SeanaEVP, General C…
$98K
Sep 8
SELL
Lee Frank D.Dir
$122K
Aug 21
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
PAULSON & CO. INC.
73.3M
2
GOLDENTREE ASSET MANAGEMENT LP
34.7M
3
ROYAL BANK OF CANADA
11.4M
4
NOMURA HOLDINGS INC
9.0M
5
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
8.0M
6
MFN Partners Management, LP
6.0M
7
Kohlberg Kravis Roberts & Co. L.P.
5.2M
8
GOLDMAN SACHS GROUP INC
5.2M
News & Activity

BHC News

About

bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Thomas J. Appio
Country
CA
Jonathan SadehExecutive Vice President, Chief Medical Officer and Head of R&D
Garen SarafianVice President & Head of Investor Relations
Jean-Jacques CharhonExecutive Vice President & Chief Financial Officer
Peers(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
BHC
$5.42-0.55%$2.0B+852.7%152.9%1500
$404.35-3.20%$2.1T30.5+3296.8%4510.0%1500
$132.58-6.05%$307.9B20.7-44.8%1012.0%1500
$88.38-2.58%$303.7B13.6+318.8%1510.7%1500
$148.08-1.13%$282.6B21.0+597.3%2564.4%1500
$181.58-1.83%$281.6B26.9+862.9%1745.9%1500
$183.40-0.23%$256.1B16.8+213.3%1482.4%1500
Sector avg-2.22%21.6+871.0%1854.0%1500